Summit Stock Skyrockets Nearly 700% YTD: Time to Sell or Hold?
The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the ...
Indaptus Therapeutics announces clinical supply agreement with BeiGene
Indaptus Therapeutics (INDP) announced a clinical supply agreement with BeiGene (BGNE). Building on Indaptus’ preclinical observation ...
Targeted Oncology17 小时
Bispecific Antibodies and ADCs Deliver a Futuristic Horizon Across Lung Cancer Settings
Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...
Regeneron's Eye Disease Drug Eylea and Immunology Drug Dupixent Support a Narrow Moat
Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...
BriaCell Therapeutics: High-Potential In Phase 3 Metastatic Breast Cancer, But Financing ...
BriaCell Therapeutics could access a $1-$5 billion market upon approval despite a sub-$30 million cap. See more on BRIA stock ...
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment
Under Indaptus' clinical supply agreement with BeiGene, the New York biotechnology company plans to advance human clinical evaluation of its cancer treatment -- called Decoy20, which is being studied ...